NCT01537068 - Desvenlafaxine vs. Placebo Treatment of Chronic Depression | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

February 29, 2012

Primary Completion Date

August 31, 2016

Study Completion Date

December 31, 2016

Conditions

Dysthymic DisorderDysthymiaChronic Depressive Disorder

Interventions

DRUG

Desvenlafaxine

Desvenlafaxine oral dose ranging from 50 to 100 mg/day

DRUG

Placebo

Matching placebo pills

Trial Locations (2)

New York State Psychiatric Institute/3 Columbus Circle Midtown, New York

Depression Evaluation Service (DES), New York State Psychiatric Institute, Columbia University Department of Psychiatry, New York